Paper - WANFANG MED ONLINE

You Position: Home > Paper

棘白菌素类抗真菌药物的药代动力学/药效动力学与优化治疗

( views:292, downloads:847 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 7

DOI:: 10.3760/cma.j.issn.1001-0939.2014.07.019

Key Word:: No keyword available

Abstract：真菌是一种条件性致病菌,是免疫抑制患者致死的主要原因.治疗真菌感染的药物有吡咯类、多烯类、棘白菌素类、氟胞嘧啶类及丙烯类等.新型抗真菌药物棘白菌素类(echinocandins)包括卡泊芬净(caspofungin)、米卡芬净(micafungin)和阿尼芬净(anidulafungin),具有独特的干扰真菌细胞壁的作用,成为传统真菌治疗的替代药物,临床应用前景较好.如何优化治疗是棘白菌素类应用中非常重要的问题,现将棘白菌素类抗真菌药物的药代动力学/药效动力学(PK/PD)的研究进展及优化治疗介绍如下.

Reference

[1]CHEN Qian,LIN Mao-hu,CHEN Meng-li,etc.Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials[J].2012,(2).
[2]Drusano GL,Walsh TJ,Hope WW,etc.Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.[J].2007,51(1).
[3]Susan J, Howard,Joanne, Livermore,Andrew, Sharp,etc.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.[J].2011,55.
[4]Jason, Cota,Michael, Carden,John R, Graybill,etc.In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.[J].2006,50.
[5]Espiritu M,Parmar R,Stevens DA,etc.Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.[J].2006,50(4).
[6]Presterl E,Enzinger S,Willinger B,etc.The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.[J].2003,48(1).
[7]David A, Stevens,Masayuki, Ichinomiya,Yukako, Koshi,etc.Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.[J].2006,50.
[8]Bai,C.Q.,Liu,Y.N.,Yuan,X.,etc.Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials.[J].2012,67(4).
[9]Vinks AA,Bleesing J,Tarin R,etc.Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.[J].2010,16(10).
[10]Gumbo T,Keirns JJ,Drusano GL,etc.Population pharmacokinetics of micafungin in adult patients.[J].2008,60(3).
[11]Lepak A,Marchillo K,Andes D,etc.In Vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.[J].2010,54(6).
[12]Lewis RE,Albert ND,Kontoyiannis DP.Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.[J].2008,61(5).
[13]Andes,D.R.,Reynolds,D.K.,VanWart,S.A.,etc.Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: Dosing strategy optimization[J].2013,57(11).
[14]Michael H, Wilke.Invasive fungal infections in infants-focus on anidulafungin.[J].2013,7.
[15]Perlin DS.Current perspectives on echinocandin class drugs.[J].2011,6(4).
[16]Tawanda, Gumbo,George L, Drusano,Weiguo, Liu,etc.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.[J].2006,50.
[17]Kauffman CA,Sobel JD,Fisher JF,etc.Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.[J].2009,48(5).
[18]Fernando C, Bizerra,Analy S A, Melo,Eduardo, Katchburian,etc.Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species.[J].2011,55.
[19]Sandhu P,Deutsch PJ,Pearson PG,etc.Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.[J].2004,48(3).
[20]Stevens DA,Knox KS,Bennett JE,etc.An official american thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients.[J].2011,183(1).
[21]Gumbo T.Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.[J].2007,20(6).
[22]Di Bonaventura G,Spedicato I,Picciani C,etc.In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies.[J].2004,48(11).
[23]Radecke C,Schulz B,Ruhnke M,etc.Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.[J].2008,27(2).
[24]Perlin DS,Lomaestro BW,Park S,etc.Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.[J].2006,26(6).
[25]Kofla G,Ruhnke M.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.[J].2011,16(4).
[26]Albert N,Lewis RE,Kontoyiannis DP,etc.Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.[J].2007,51(6).
[27]Rex JH,Paetznick V,Lozano-Chiu M,etc.In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.[J].2001,45(1).
[28]Stevens,D.A..Advances in systemic antifungal therapy[J].2012,30(6).
[29]Slavin MA,Sorrell TC,Chen SC.Echinocandin antifungal drugs in fungal infections: a comparison.[J].2011,71(1).
[30]Pound MW,Townsend ML,Drew RH.Echinocandin pharmacodynamics: review and clinical implications.[J].2010,65(6).
[31]Liu W,Drusano GL,Gumbo T,etc.Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.[J].2005,49(12).
[32]Liu W,Drusano GL,Hsu V,etc.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.[J].2007,51(3).
[33]Marchillo K,Ashbeck J,Pfaller MA,etc.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.[J].2008,52(2).
[34]Tam VH,Chi J,Wiederhold NP,etc.Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.[J].2004,190(8).
[35]Johnson LB,Kale Pradhan PB,Morgan G,etc.Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.[J].2010,30(12).
[36]Ta P,Hoang BT,Nguyen KT.Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.[J].2009,53(8).
[37]Cornely,O.A.,Bassetti,M.,Calandra,T.,etc.ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients[J].2012,18(Suppl.7).
[38]Ernst EJ,Klepser ME,Pfaller MA.Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.[J].2000,44(4).